Why the study?
Direct oral anticoagulants combined with antiplatelet therapy have shown efficacy in secondary prevention of atherosclerotic disease, but their anti-inflammatory effects and mechanisms remain to be clarified.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Tanaka et al. (2020) conducted a review in Stable cardiovascular disease (n=27,395). Rivaroxaban vs. Aspirin 100 mg once daily was evaluated on Composite cardiovascular endpoint (HR 0.76, 95% CI 0.66-0.86, p=<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: